Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-MSLN/Mesothelin (h7D9.v3)
Copy Product Info
😃Good
Catalog No. T9901A-1613
Alias RG7600 antibody
Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) that specifically targets MSLN. It is applicable in research on ovarian cancer, mesothelioma, and pancreatic cancer.
Anti-MSLN/Mesothelin (h7D9.v3)
Anti-MSLN/Mesothelin (h7D9.v3)
Copy Product Info😃Good
Catalog No. T9901A-1613Alias RG7600 antibody
Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) that specifically targets MSLN. It is applicable in research on ovarian cancer, mesothelioma, and pancreatic cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) that specifically targets MSLN. It is applicable in research on ovarian cancer, mesothelioma, and pancreatic cancer. |
| Synonyms | RG7600 antibody |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Anti-MSLN/Mesothelin (h7D9.v3) | purchase Anti-MSLN/Mesothelin (h7D9.v3) | Anti-MSLN/Mesothelin (h7D9.v3) cost | order Anti-MSLN/Mesothelin (h7D9.v3)
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.